TeamDrive
RUS

About us

Team Drive was founded in 2011 as the brainchild of two of Russia’s most successful and prominent business leaders, Leonid Melamed (ex-CEO of Sistema JSFC*, Russia’s largest publically traded holding, and previously CEO of Rosno, Russia’s largest insurer and MTS, Russia’s largest telecommunications operator) and Vladimir Gurdus (ex-CEO of Medsi, Russia’s largest private healthcare provider).

Having spent two decades successfully conceiving, building, operating and exiting  multi-billion-dollar brands and businesses in Russia and the CIS, Leonid and Vladimir came to the conclusion that not only could Russian assets and businesses be created that were highly competitive in Russia, but highly competitive at global scale, with concomitant returns to equity. In other words, that Russian assets, capital, talent, ideas, companies and brands represent a vast and largely untapped reservoir of investor and customer value potential, both in a Russian market context as well as in a global market context. Team Drive was created specifically to unlock this untapped value potential.

We offer an end-to-end asset management and value augmentation service in Russia with a focus on distressed or underperforming assets going all the way from initial control, creditor/investor alignment, goals/objectives definition, detailed brand and market differentiation strategy to business planning, operational execution and optimal exit, operating to global best practices. 


*Sistema JSFC is the largest publicly-traded diversified holding company in Russia and the CIS. Incorporated in 1993, Sistema is now one of Russia's top ten companies by revenues and is one of the largest investment companies in the world. The group owns a diverse set of public and private companies, which it holds in two distinct portfolios.

Media Center

  • 26 September 2017

    Iranian biotech drugs replaced American ones in Russia

    Iranian biotech medicines exported to Russia have taken over the country’s market 100% and have replaced their American versions, according to National Talents Foundation.

  • 26 September 2017

    Pfizer and LabCentral announced opening of a new facility

    LabCentral and Pfizer announced plans to open LabCentral 610, a new LabCentral offering located at Pfizer’s Kendall Square Worldwide Research and Development campus, Cambridge, Massachusetts, U.S. The facility is slated to open in December and will house up to six early- to mid-stage companies.

  • 25 September 2017

    Russian University creates a bank of biomolecules for new drugs

    The research activities of Genomic and Regenerative Medicine Center established at the School of Biomedicine in the Far Eastern Federal University (FEFU) will be based on unique natural resources of the Russian Far East. The scientists will study the biodiversity of the region, including marine organisms, create a bank of biomolecules for new drugs, and introduce innovative diagnostic and treatment methods into routine medical practice.

  • 25 September 2017

    Transition to multicomponent preventive drugs is necessary

    During the second BIOTECHMED conference held in Gelendzhik, the representatives of Nacimbio, a company which is part of Rostec Corporation, participated in panel discussions on preventive vaccination and expansion of the National Immunization Calendar.

Read more